FrancophonIA/ELRC3.0 huggingface dataset:
English: The duration of treatment is up to 1 year based on the doctor's judgement for you, or the child you are caring for.
Slovenian: Vaše zdravljenje ali zdravljenje otroka, za katerega skrbite, traja do 1 leta, odvisno od zdravnikove presoje.
English: Congestive heart failure, cardiomyopathy, arrhythmia, pericarditis
Slovenian: kongestivno srčno popuščanje, kardiomiopatija, aritmije, perikarditis
English: For adult patients who use 1.0 g/kg ViraferonPeg monotherapy, dose reduction may be accomplished by reducing the prescribed volume by one-half or by utilizing a lower dose strength as shown in Table 3c.
Slovenian: Za odrasle bolnike, ki jemljejo 1,0 g/kg zdravila ViraferonPeg v monoterapiji, zmanjšanje odmerka dosežemo z zmanjšanjem predpisanega volumna za pol ali z uporabo manjše jakosti, kot je prikazano v preglednici 3c.
English: Some people get depressed when taking this medicine alone or in combination treatment with ribavirin, and in some cases people have had thoughts about threatening the life of others, suicidal thoughts or aggressive behaviour (sometimes directed against others).
Slovenian: V nekaterih primerih so se pri ljudeh pojavile misli, kako ogroziti življenja drugih, samomorilne misli ali agresivno vedenje (včasih usmerjeno proti drugim).
English: If treatment with alpha interferon is judged necessary in these patients, the presence of psychiatric co-morbidities and the potential for other substance use should be carefully assessed and adequately managed before initiating therapy.
Slovenian: Če ocenite, da je pri takšnih bolnikih potrebno zdravljenje z interferonom alfa, morate pri njih skrbno preveriti, ali imajo morda kakšno sočasno psihiatrično motnjo in če obstaja možnost uživanja opojnih substanc, ter uvesti ustrezne ukrepe še pred uvedbo zdravila.
English: Caution should be used when adding ViraferonPeg and ribavirin to HAART therapy (see ribavirin SmPC).
Slovenian: Pri dodajanju zdravila ViraferonPeg in ribavirina terapiji HAART je potrebna previdnost (glejte SmPC za ribavirin).
English: Dispose of the syringe and needles safely in a closed container.
Slovenian: Brizgo in igli varno zavrzite v zaprt vsebnik.
English: Do not use if it is discoloured or if particles are present.
Slovenian: Ne uporabljajte je, če je obarvana ali če so v njej vidni delci.
English: Using a sterilised injection syringe and injection needle, 0.7 ml of water for injections is injected into the vial of ViraferonPeg.
Slovenian: S sterilno injekcijsko brizgo in injekcijsko iglo injicirajte 0,7 ml vode za injekcije v vialo zdravila ViraferonPeg.
English: 1 vial of powder, 1 ampoule of solvent
Slovenian: 1 viala praška, 1 ampula vehikla
English: Ocular changes
Slovenian: Očesne spremembe
English: Use the reconstituted solution (solution you prepared by adding water for injection to the ViraferonPeg powder) immediately or within 24 hours when stored in a refrigerator (2°C - 8°C).
Slovenian: Rekonstituirano raztopino (raztopino, ki ste jo pripravili z dodajanjem vode za injekcije k ViraferonPeg prašku) uporabite takoj ali v roku 24 ur, če ste jo medtem shranili v hladilniku (2 °C - 8 °C).
English: a: Response to treatment was defined as undetectable HCV-RNA at 24 weeks post-treatment lower limit of detection=125IU/ml b: n = number of responders/number of subjects with given genotype, and assigned treatment duration.
Slovenian: a: Odziv na zdravljenje je bil opredeljen kot nemerljiva HCV-RNA v 24. tednu po zdravljenju, spodnja meja detekcije = 125 i.e./ml.
English: ViraferonPeg in combination with ribavirin (bitherapy) is indicated for the treatment of CHC infection in adult patients who are previously untreated including patients with clinically stable HIV co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy (see section 5.1).
Slovenian: Zdravilo ViraferonPeg v kombinaciji z ribavirinom (dvojna terapija) je indicirano za zdravljenje okužbe s CHC pri odraslih bolnikih, ki predhodno niso bili zdravljeni, vključno s tistimi bolniki, ki imajo klinično stabilno okužbo s HIV, in pri tistih odraslih bolnikih, pri katerih je bila prejšnja kombinirana terapija z interferonom alfa (pegiliranim ali nepegiliranim) in ribavirinom oziroma monoterapija z interferonom alfa neuspešna (glejte poglavje 5.1).
English: o Taking this medicine in combination with ribavirin and an anti-HIV medicine(s) may increase the risk of lactic acidosis, liver failure, and blood abnormalities: reduction in number of red blood cells, white blood cells and blood clotting cells called platelets.
Slovenian: o Če uporabljate to zdravilo v kombinaciji z ribavirinom in z zdravili proti HIV, se lahko poveča tveganje za pojav laktacidoze, jetrne odpovedi in nenormalne krvne izvide: zmanjšanje števila rdečih krvnih celic, belih krvnih celic in celic za strjevanje krvi, ki jim pravimo trombociti.
English: Aggression, agitation, anger, mood altered, abnormal behaviour, nervousness, sleep disorder, libido decreased, apathy, abnormal dreams, crying
Slovenian: agresivnost, vznemirjenost, jeza, spremembe razpoloženja, nenormalno vedenje, živčnost, motnje spanja, zmanjšan libido, apatičnost, nenormalne sanje, jok
English: Palpitations, tachycardia
Slovenian: palpitacije, tahikardija
English: If week 12 HCV-RNA is positive and decreased ≥ 2log10 from baseline, then retest HCV-RNA at week 24 and if positive, patients to stop therapy.
Slovenian: Če je HCV-RNA v 12. tednu pozitivna in virusno breme za ≥ 2 log10 manjše od začetne vrednosti, v 24. tednu ponovno opravite določanje HCV-RNA in, če je izvid pozitiven, naj bolnik preneha z zdravljenjem.
English: Reduce only ribavirin daily dose (see note 1)
Slovenian: Zmanjšajte le dnevni odmerek ribavirina (glejte opombo 1) v primeru:
English: The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period.
Slovenian: Zdravljenje je trajalo 48 tednov, bolnike pa so spremljali še 6 mesecev, razen tistih, ki so bili okuženi z genotipoma 2 ali 3 in so imeli virusno breme < 800.000 i.e./ml (Amplicor).
English: Table 3a Dose modification guidelines for ViraferonPeg monotherapy in adults based on laboratory parameters
Slovenian: Preglednica 3a Smernice za prilagoditev odmerka za monoterapijo z zdravilom ViraferonPeg pri odraslih bolnikih, ki temeljijo na laboratorijskih vrednostih
English: Do not use ViraferonPeg
Slovenian: Ne uporabljajte zdravila ViraferonPeg
English: ViraferonPeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy (see section 5.1).
Slovenian: Zdravilo ViraferonPeg je v kombinaciji z ribavirinom in boceprevirjem (trojna terapija) indicirano za zdravljenje kronične okužbe z virusom hepatitisa C (CHC - chronic hepatitis C) genotipa 1 pri odraslih bolnikih (18 let ali več) s kompenzirano jetrno boleznijo, ki predhodno niso bili zdravljeni ali pa je bilo predhodno zdravljenje neuspešno (glejte poglavje 5.1).
English: Amnesia, memory impairment, syncope, migraine, ataxia, confusion, neuralgia, paraesthesia, hypoaesthesia, hyperaesthesia, hypertonia, somnolence, disturbance in attention, tremor, dysgeusia
Slovenian: amnezija, motnje spomina, sinkopa, migrena, ataksija, zmedenost, nevralgija, parestezije, hipoestezija, hiperestezija, hipertonija, somnolenca, motnje pozornosti, tremor, disgevzija
English: *, dry skin *, rash
Slovenian: *, suha koža
English: Discontinue ribavirin if CrCL < 50ml/min
Slovenian: Kreatininski očistek ribavirin ukinite, če se vrednost CrCl zmanjša pod 50 ml/min
English: This means that it is injected through a short needle into the fatty tissue just under the skin.
Slovenian: To pomeni, da se s kratko iglo injicira v maščevje tik pod kožo.
English: In the ViraferonPeg monotherapy study, the Quality of Life was generally less affected by 0.5 microgram/kg of ViraferonPeg than by either 1.0 microgram/kg of ViraferonPeg once weekly or 3 MIU of interferon alfa-2b three times a week.
Slovenian: V študiji monoterapije z zdravilom ViraferonPeg je bil vpliv na kakovost življenja običajno manjši pri bolnikih, ki so prejemali po 0,5 mikrograma/kg zdravila ViraferonPeg, kot pri tistih, ki so prejemali bodisi 1,0 mikrogram/kg zdravila ViraferonPeg enkrat na teden ali 3 mio i.e. interferona alfa-2b trikrat na teden.
English: Co-administration of theophylline with the product (ViraferonPeg) may increase the blood concentrations of theophylline.
Slovenian: Sočasna uporaba teofilina z zdravilom ViraferonPeg lahko zviša koncentracije teofilina v krvi.
English: Fungal infection, influenza, oral herpes, otitis media, pharyngitis streptococcal, nasopharyngitis, sinusitis
Slovenian: glivična okužba, gripa, herpes na ustih, otitis media, streptokokni faringitis, nazofaringitis, sinusitis
English: In a separate trial, 224 patients with genotype 2 or 3 received ViraferonPeg, 1.5 micrograms/kg subcutaneously, once weekly, in combination with ribavirin 800 mg -1,400 mg p.o. for 6 months (based on body weight, only three patients weighing > 105 kg, received the 1,400 mg dose) (Table 10).
Slovenian: V ločenem preskušanju je 224 bolnikov z genotipom 2 ali 3 prejemalo zdravilo ViraferonPeg v odmerku 1,5 mikrograma/kg subkutano enkrat na teden v kombinaciji z ribavirinom od 800 mg do 1.400 mg peroralno 6 mesecev (glede na telesno maso, samo 3 bolniki s telesno maso > 105 kg so prejeli odmerek 1.400 mg) (preglednica 10).
English: Reproduction studies of ViraferonPeg have not been performed.
Slovenian: Študije vpliva na sposobnost razmnoževanja z zdravilom ViraferonPeg niso bile izvedene.
English: Patients with creatinine clearance < 50 ml/minute must not be treated with ViraferonPeg in combination with ribavirin (bitherapy or tritherapy) (see section 4.3).
Slovenian: Bolnikov z očistkom kreatinina < 50 ml/minuto ne smete zdraviti z zdravilom ViraferonPeg v kombinaciji z ribavirinom (dvojna ali trojna terapija) (glejte poglavje 4.3).
English: Table 12 Predictive value of in-treatment Virologic Response while on ViraferonPeg 1.5 µg/kg/ribavirin 800-1,400 mg combination therapy Negative
Slovenian: Preglednica 12 Napovedna vrednost virološkega odziva med kombiniranim zdravljenjem z zdravilom ViraferonPeg 1,5 µg/kg in ribavirinom 800 - 1.400 mg Negativna
English: For patients on ViraferonPeg monotherapy: refer to monotherapy dose reduction guidelines section for dose reduction.
Slovenian: Za bolnike, ki se zdravijo z monoterapijo z zdravilom ViraferonPeg: glejte smernice za zmanjševanje odmerka pri monoterapiji.
English: Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and height percentile were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3
Slovenian: Izguba telesne mase in zastoj rasti sta bila zelo pogosta med zdravljenjem (ob koncu zdravljenja je znašalo povprečno zmanjšanje percentila telesne mase in percentila telesne višine glede na začetno vrednost 15 percentilov oz. 8 percentilov), zmanjšana je bila tudi hitrost rasti (pod 3. percentilom pri 70 % bolnikov).
English: Mitochondrial toxicity
Slovenian: Toksičnost za mitohondrije:
English: Therefore, you must not take this medicine at the same time as telbivudine.
Slovenian: Ti učinki so lahko tudi resnejši, zato tega zdravila ne smete uporabljati sočasno s telbivudinom.
English: If you are exceptionally thin, use only the thigh or outer surface of the arm for injection.
Slovenian: Če ste zelo suhi, za injiciranje uporabljajte le stegno ali zunanjo stran nadlakti.
English: Each pre-filled pen is for single use only.
Slovenian: Vsak napolnjeni injekcijski peresnik je namenjen enkratni uporabi.
English: Adding treatment with alfa interferons alone or in combination with ribavirin may increase the risk in this patient subset.
Slovenian: Dodajanje monoterapije z alfa interferoni ali kombinirane terapije z alfa interferoni in ribavirinom lahko poveča tveganje pri tej skupini bolnikov.
English: Detailed instructions for subcutaneous administration are provided at the end of this leaflet (see ANNEX TO THE PACKAGE LEAFLET “How to use the ViraferonPeg pre-filled pen”).
Slovenian: Podrobna navodila za podkožno injiciranje so priložena na koncu teh navodil (glejte PRILOGO "Kako uporabljati napolnjeni injekcijski peresnik ViraferonPeg" NA KONCU NAVODIL).
English: Acute hypersensitivity reactions including angioedema, anaphylaxis and anaphylactic reactions including anaphylactic shock, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, systemic lupus erythematosus
Slovenian: akutne preobčutljivostne reakcije, ki vključujejo angioedem, anafilaksijo in anafilaktične reakcije, vključno z anafilaktičnim šokom, idiopatsko trombocitopenično purpuro, trombotično trombocitopenično purpuro in sistemskim eritematoznim lupusom
English: Subcutaneous use Read the package leaflet before use.
Slovenian: subkutana uporaba Pred uporabo preberite priloženo navodilo!
English: Neutrophil and white cell count reductions at the end of week 4 correlated with the dose of ViraferonPeg.
Slovenian: Tudi zmanjšanje števila nevtrofilcev in levkocitov ob koncu 4. tedna je bilo sorazmerno odmerku zdravila ViraferonPeg.
English: Reduce ViraferonPeg to one-half dose if:
Slovenian: Zmanjšajte odmerek zdravila ViraferonPeg na polovico v primeru:
English: ViraferonPeg plus ribavirin
Slovenian: ViraferonPeg + ribavirin
English: It is recommended that all patients be treated with bitherapy for 24 weeks, except for HCV/HIV co-infected patients who should receive 48 weeks of treatment.
Slovenian: Priporočljivo je, da se vsi bolniki z dvojno terapijo zdravijo 24 tednov, razen tisti, ki imajo sočasno okužbo s HCV/HIV.
English: Haematological abnormalities in HCV/HIV co-infected patients HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Slovenian: Hematološke motnje pri bolnikih, sočasno okuženih s HCV/HIV Bolniki, ki so sočasno okuženi s HCV/HIV ter se zdravijo s peginterferonom alfa-2b/ribavirinom in s terapijo HAART, imajo lahko povečano tveganje za nastanek hematoloških motenj (v obliki nevtropenije, trombocitopenije in anemije) v primerjavi s tistimi, ki so okuženi samo s HCV.
English: The solution should be clear and colourless before use.
Slovenian: Raztopina mora biti pred uporabo bistra in brezbarvna.
English: Hold the syringe with the needle in the vial pointing up.
Slovenian: Držite brizgo z iglo v viali obrnjeno navzgor.
English: Rare side effects (may affect up to 1 in 1,000 people): - convulsion (“fit”), - blood or clots in stool (or black, tarry stool),
Slovenian: Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): konvulzije (epileptični napadi), kri ali krvni strdki v blatu (ali črno, smolasto blato).
English: Limited safety data (N= 25) are available in co-infected patients with CD4+ cell counts < 200/µl (see section 4.4).
Slovenian: Za sočasno okužene bolnike s številom celic CD4+ < 200/µl so na voljo le omejeni podatki o varnosti (N = 25) (glejte poglavje 4.4).
English: After administering the dose, the ViraferonPeg pre-filled pen and any unused solution contained in it is to be disposed of in accordance with local requirements.
Slovenian: Po dajanju odmerka napolnjen injekcijski peresnik ViraferonPeg, skupaj z morebitno neporabljeno raztopino v njem, zavrzite v skladu z lokalnimi predpisi.
English: Micturition frequency, polyuria, urine abnormality
Slovenian: pogosto uriniranje, poliurija, nenormalen urin
English: You should use a different place each time you give yourself an injection.
Slovenian: Za injiciranje morate uporabiti vsakič drugo mesto.
English: ViraferonPeg has a potential to depegylate to free interferon alfa-2b.
Slovenian: Zdravilo ViraferonPeg ima sposobnost depegilacije do prostega interferona alfa-2b.
English: Cleanse and disinfect the skin where the injection is to be made.
Slovenian: Očistite in dezinficirajte kožo na mestu, kamor boste injicirali, in počakajte, da se posuši.
English: Multiple-dose pharmacokinetic properties for ViraferonPeg and ribavirin (capsules and oral solution) in children and adolescent patients with chronic hepatitis C have been evaluated during a clinical study.
Slovenian: V klinični študiji so ovrednotili farmakokinetične lastnosti zdravila ViraferonPeg in ribavirina (kapsule in peroralna raztopina) pri otrocih in mladostnikih s kroničnim hepatitisom C po jemanju večkratnih odmerkov.
English: Excipients with known effect: Each vial contains 40 mg of sucrose per 0.5 ml.
Slovenian: Pomožne snovi z znanim učinkom: Ena viala vsebuje 40 mg saharoze na 0,5 ml zdravila.
English: When administered in combination with other interferon preparations, suppressive effect on bone marrow function may be strengthened and aggravation of blood cell reduction such as white blood cells decreased may occur.
Slovenian: Pri sočasni uporabi z drugimi zdravili z interferonom se lahko okrepi zaviranje delovanja kostnega mozga, kar lahko privede do večjega zmanjšanja števila krvnih celic, kot na primer zmanjšanja števila belih krvnih celic.
English: HVL (>600,000 IU/ml)
Slovenian: HVL (>600.000 i.e./ml
English: Response to the treatment was measured by Sustained Virologic Response (SVR) which is defined as undetectable HCV-RNA at 24 weeks post-treatment (see Table 11).
Slovenian: Odziv bolnikov na zdravljenje so merili na podlagi trajnega virološkega odziva (SVR - Sustained Virologic Response), ki je opredeljen kot nemerljiva koncentracija HCV-RNA v 24. tednu po koncu zdravljenja (glejte preglednico 11).
English: As monotherapy the ViraferonPeg regimen is 0.5 or 1.0 g/kg/week.
Slovenian: Režim odmerjanja zdravila ViraferonPeg v monoterapiji je 0,5 ali 1,0 g/kg/teden.
English: Interferon alfa-2b (3 MIU) + ribavirin (1,000/1,200 mg)
Slovenian: Interferon alfa-2b (3 mio i.e.) + ribavirin (1.000/1.200 mg)
English: - The active substance is peginterferon alfa-2b.
Slovenian: - Učinkovina je peginterferon alfa-2b.
English: Hypothyroidism, hyperthyroidism Metabolism and nutrition disorders Very common:
Slovenian: hipotiroidizem, hipertiroidizem Presnovne in prehranske motnje Zelo pogosti:
English: Diabetes mellitus, hypertriglyceridaemia
Slovenian: sladkorna bolezen, hipertrigliceridemija
English: If you are an HCV/HIV co-infected adult patient receiving HAART, the addition of this medicine and ribavirin may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
Slovenian: Če ste odrasel bolnik, sočasno okužen z virusoma HCV in HIV, in se zdravite s shemo HAART, lahko dodatek tega zdravila in ribavirina pri vas poveča tveganje za pojav laktacidoze, jetrne odpovedi in nastanka motenj krvi (zmanjšanje števila rdečih krvnih celic, ki prenašajo kisik, določenih belih krvnih celic, s katerimi se telo bojuje proti okužbam, in celic za strjevanje krvi, ki jim pravimo trombociti).
English: Dose of peginterferon alfa-2b
Slovenian: Odmerek peginterferona alfa-2b
English: Very rare side effects (may affect up to 1 in 10,000 people): - aplastic anaemia, stroke (cerebrovascular events), toxic epidermal necrolysis/Stevens Johnson Syndrome/erythema multiforme (a spectrum of rashes with varying degree of severity including death which may be associated with blisters in the mouth, nose, eyes and other mucosal membranes and sloughing of the affected area of the skin).
Slovenian: Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): - aplastična anemija, možganska kap (cerebrovaskularni inzult), toksična epidermalna nekroliza/Stevens-Johnsonov sindrom/multiformni eritem (spekter izpuščajev različnih stopenj jakosti, vključno s smrtnimi, ki so lahko povezani s pojavom mehurjev na ustni, nosni ali očesni sluznici ter na drugih sluznicah in luščenje prizadetega predela kože).
English: The following other side effects (not listed above) have occurred with the combination of this medicine and ribavirin capsules (adults) in HCV/HIV co-infected patients receiving HAART: - oral candidiasis (oral thrush), - defective metabolism of fat, - CD4 lymphocytes decreased, - appetite decreased, - back pain, - hepatitis, - limb pain, - and various laboratory blood values abnormalities.
Slovenian: Naslednji drugi neželeni učinki (ki niso navedeni zgoraj) so se pojavili pri uporabi kombinacije tega zdravila in kapsul ribavirina (odrasli) pri bolnikih, ki so bili sočasno okuženi z virusoma HCV in HIV in so prejemali zdravljenje s shemo HAART: - peroralna kandidiaza (sor v ustih), - motnje presnove maščob, - zmanjšano število limfocitov CD4, - zmanjšan apetit, - bolečine v hrbtu, - hepatitis, - bolečine v udih, - nenormalni izvidi različnih laboratorijskih preiskav krvi.
English: There is, however, only a modest increase in biologic activity as measured by a bioassay.
Slovenian: Po večkratnem odmerjanju pride do kopičenja imunoreaktivnih interferonov, vendar je zvišanje biološke aktivnosti, izmerjeno z bioanalizo, skromno.
English: • Remove the yellow paper from the needle cap before attaching the needle ("Push-On Needle") to the pre-filled pen (see Figure 5),
Slovenian: • Preden iglo ("igla na potisk") namestite na napolnjeni injekcijski peresnik, s pokrovčka igle odstranite rumeni papir (glejte sliko 5).
English: Extreme care must be taken to avoid pregnancy in female patients or in partners of male patients taking ViraferonPeg in combination with ribavirin.
Slovenian: Posebna previdnost je potrebna pri bolnicah ter tudi pri partnerkah bolnikov moškega spola, ki jemljejo zdravilo ViraferonPeg v kombinaciji z ribavirinom, da ne bi zanosile.
English: Current treatment guidelines should be consulted as to whether a liver biopsy is needed prior to commencing treatment.
Slovenian: Podatek o tem, ali je pred začetkom zdravljenja potrebna biopsija jeter, najdete v tekočih smernicah za zdravljenje.
English: ViraferonPeg/ribavirin retreatment of prior treatment failures In a non-comparative trial, 2,293 patients with moderate to severe fibrosis who failed previous treatment with combination alpha interferon/ribavirin were retreated with ViraferonPeg, 1.5 micrograms/kg subcutaneously, once weekly, in combination with weight adjusted ribavirin.
Slovenian: Ponovno zdravljenje z zdravilom ViraferonPeg in ribavirinom po predhodno neuspešnem zdravljenju V neprimerjalnem preskušanju so 2.293 bolnikov z zmerno do hudo fibrozo, pri katerih je bilo predhodno zdravljenje s kombinacijo interferona alfa in ribavirina neuspešno, ponovno zdravili z zdravilom ViraferonPeg v odmerku 1,5 mikrograma/kg subkutano enkrat na teden, v kombinaciji z ribavirinom v odmerku, prilagojenem glede na telesno maso.
English: Table 9 Sustained response rates with ViraferonPeg + ribavirin (by ribavirin dose, genotype and viral load)
Slovenian: Preglednica 9 Delež trajnega odziva z zdravilom ViraferonPeg + ribavirinom (glede na odmerek ribavirina, genotip in virusno breme)
English: When administered in combination with other interferon preparations, effect of immunosuppressive therapy may be weakened in transplant (kidney, bone marrow, etc.) patients.
Slovenian: Sočasna uporaba z drugimi zdravili z interferonom lahko pri bolnikih s presajenim organom (ledvica, kostni mozeg, itd.) oslabi učinek imunosupresivnega zdravljenja.
English: ViraferonPeg (1.5 µg/kg/ week) + ribavirin (800 mg)
Slovenian: ViraferonPeg (1,5 µg/kg/ teden) + ribavirin (800 mg)
English: - Tap the top of the ampoule of solvent gently to make sure that all the liquid is at the bottom of the ampoule.
Slovenian: - Narahlo potrkajte ob vrh ampule z vehiklom oz. topilom, tako da bo vsa tekočina stekla na dno ampule.